Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV001091510 | SCV001247602 | likely pathogenic | not provided | 2022-12-01 | criteria provided, single submitter | clinical testing | ABCA4: PP4:Strong, PM2, PM3 |
Invitae | RCV001091510 | SCV004292485 | pathogenic | not provided | 2023-05-21 | criteria provided, single submitter | clinical testing | This variant disrupts the p.Asp1918 amino acid residue in ABCA4. Other variant(s) that disrupt this residue have been determined to be pathogenic (Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ABCA4 protein function. ClinVar contains an entry for this variant (Variation ID: 871507). This missense change has been observed in individual(s) with ABCA4-related conditions (PMID: 27939946; Invitae). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces aspartic acid, which is acidic and polar, with valine, which is neutral and non-polar, at codon 1918 of the ABCA4 protein (p.Asp1918Val). |